SG10202003100XA - Bacteria Engineered to Reduce Hyperphenylalaninemia - Google Patents

Bacteria Engineered to Reduce Hyperphenylalaninemia

Info

Publication number
SG10202003100XA
SG10202003100XA SG10202003100XA SG10202003100XA SG10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA
Authority
SG
Singapore
Prior art keywords
bacteria engineered
hyperphenylalaninemia
reduce
reduce hyperphenylalaninemia
engineered
Prior art date
Application number
SG10202003100XA
Other languages
English (en)
Inventor
Dean Falb
Vincent Isabella
Jonathan Kotula
Paul Miller
Sarah Rowe
Yves Millet
Original Assignee
Synlogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic Operating Co Inc filed Critical Synlogic Operating Co Inc
Publication of SG10202003100XA publication Critical patent/SG10202003100XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10202003100XA 2015-05-13 2016-05-13 Bacteria Engineered to Reduce Hyperphenylalaninemia SG10202003100XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562161137P 2015-05-13 2015-05-13
US201562256052P 2015-11-16 2015-11-16

Publications (1)

Publication Number Publication Date
SG10202003100XA true SG10202003100XA (en) 2020-05-28

Family

ID=56117975

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202003100XA SG10202003100XA (en) 2015-05-13 2016-05-13 Bacteria Engineered to Reduce Hyperphenylalaninemia

Country Status (12)

Country Link
US (6) US9889164B2 (fr)
EP (2) EP3294760B1 (fr)
JP (3) JP6843768B2 (fr)
AU (2) AU2016262569B9 (fr)
BR (1) BR112017024384A2 (fr)
CA (1) CA2985819A1 (fr)
ES (1) ES2881384T3 (fr)
IL (2) IL296538A (fr)
PL (1) PL3294760T3 (fr)
SG (1) SG10202003100XA (fr)
WO (1) WO2016183531A1 (fr)
ZA (1) ZA201707678B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054471T2 (hu) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Immunmodulációs módszerek és készítmények
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2016183532A1 (fr) * 2015-05-13 2016-11-17 Synlogic, Inc. Bactéries modifiées pour traiter une maladie ou un trouble
WO2016183531A1 (fr) * 2015-05-13 2016-11-17 Synlogic, Inc. Bactéries génétiquement modifiées pour réduire l'hyperphénylalaninémie
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
EP3461337A1 (fr) 2015-05-06 2019-04-03 Snipr Technologies Limited Modification de populations microbiennes et de microbiotes
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
PL3377518T3 (pl) * 2015-11-16 2022-09-26 Synlogic Operating Company, Inc. Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
WO2018112194A1 (fr) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procédés pour moduler la croissance d'une cellule bactérienne intestinale génétiquement modifiée
WO2018183685A1 (fr) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Méthodes de régulation de l'expression génique dans une cellule
US20180362590A1 (en) * 2017-04-14 2018-12-20 Synthetic Genomics, Inc. Polypeptides with type v crispr activity and uses thereof
WO2018237198A1 (fr) 2017-06-21 2018-12-27 Synlogic Operating Company, Inc. Bactéries pour le traitement de troubles
SG11202001797TA (en) 2017-09-08 2020-03-30 New Portal Ltd Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
CN107904222B (zh) * 2017-11-30 2019-10-08 江南大学 一种热稳定性提高的l-氨基酸脱氨酶突变体及其构建方法
MX2020005875A (es) * 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
WO2020132017A1 (fr) * 2018-12-20 2020-06-25 University Of South Carolina Traitements pharmabiotiques pour troubles métaboliques
WO2020223345A1 (fr) 2019-04-29 2020-11-05 Antipov Eugene Dénombrement de micro-organismes génétiquement modifiés par des techniques de comptage de cellules vivantes
AU2020288624A1 (en) 2019-06-04 2022-02-03 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
AU2020297586A1 (en) * 2019-06-21 2022-02-10 Ginkgo Bioworks, Inc. Optimized bacteria engineered to treat disorders involving the catabolism of leucine, isoleucine, and/or valine
CN110257291B (zh) * 2019-06-25 2021-07-23 北京大学 一株耐受镍离子毒性的无色杆菌及其应用
US20220340621A1 (en) 2019-09-27 2022-10-27 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
CA3177479A1 (fr) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Plateformes d'administration de bacteries immunostimulatrices et leur utilisation pour l'administration de produits therapeutiques
WO2021144473A2 (fr) 2020-01-17 2021-07-22 Université Catholique de Louvain Bactérie génétiquement modifiée présentant une intégrité d'enveloppe modifiée et ses utilisations
EP4110283A4 (fr) * 2020-02-25 2024-02-28 Synlogic Operating Co Inc Bactéries recombinées modifiées pour traiter des maladies associées à l'acide urique et leurs méthodes d'utilisation
EP4121525A1 (fr) 2020-03-20 2023-01-25 Synlogic Operating Company, Inc. Micro-organismes modifiés pour réduire l'hyperphénylalaninémie
WO2021207647A1 (fr) * 2020-04-09 2021-10-14 Computational International LLC Médicaments à petites molécules utilisés comme agents thérapeutiques ciblés
WO2022006424A2 (fr) * 2020-07-02 2022-01-06 The Regents Of The University Of Californa Réponses de lymphocytes t à mémoire persistante à un cancer et à des antigènes de maladie infectieuse par manipulation de voies cataboliques d'acides aminés
WO2022036159A2 (fr) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Vaccins à base de bactéries immunostimulatrices, agents thérapeutiques et plateformes d'administration d'arn
WO2022103673A2 (fr) * 2020-11-10 2022-05-19 Fridkis Hareli Masha Compositions de peptides aléatoires d'épitope incorporés (eerp) pour le traitement d'états à médiation immunitaire, et procédés d'utilisation
WO2022120028A2 (fr) 2020-12-02 2022-06-09 Synlogic Operating Company, Inc. Micro-organismes modifiés
CN112501098B (zh) * 2020-12-11 2023-01-03 上海陶宇晟生物技术有限责任公司 具有降解苯丙氨酸能力的工程益生菌
CN116847860A (zh) 2020-12-31 2023-10-03 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
CN112662606A (zh) * 2021-01-06 2021-04-16 中国科学院分子植物科学卓越创新中心 用于治疗苯丙酮尿症的工程益生菌
CN112662607A (zh) * 2021-01-07 2021-04-16 上海陶宇晟生物技术有限责任公司 具备表面展示苯丙氨酸解氨酶的工程益生菌
CN117479929A (zh) * 2021-06-24 2024-01-30 龙沙格林伍德有限公司 控制活性物质向消化道施用的方法
WO2023086796A2 (fr) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Bactéries immunostimulatrices pour convertir des macrophages en un phénotype pouvant être traité, et diagnostic compagnon pour identifier des sujets pour un traitement
CN116836899A (zh) * 2022-03-02 2023-10-03 和度生物技术(上海)有限公司 一种用于治疗高苯丙氨酸血症的工程微生物及其用途
CN114717172B (zh) * 2022-03-21 2022-09-23 江南大学 合成l-缬氨酸的大肠杆菌及其构建方法与应用
CN116463362B (zh) * 2023-06-15 2023-09-19 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (zh) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (fr) 1998-12-02 2003-03-26 Univ Boston Reseaux de genes destines a controler l'expression genetique
EP1034787A1 (fr) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Souches de lactobacillus capables de prévenir la diarrhée causée des bactéries pathogènes
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (zh) * 2008-05-22 2012-03-07 北京三元基因工程有限公司 一种活性乳酸乳球菌制品的制备方法
EP2344626B1 (fr) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Colonisation réduite de microbes au niveau de la muqueuse
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
EP2655624B1 (fr) 2010-12-23 2017-11-29 Biogen MA Inc. Peptides coupleurs et polypeptides les comportant
US9017961B2 (en) * 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
LT2864491T (lt) * 2012-06-22 2018-12-27 Phytogene, Inc. Fermentai ir stireno sintezės būdai
US20150246083A1 (en) 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
US20150246085A1 (en) * 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
US9951340B2 (en) 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
WO2016183531A1 (fr) 2015-05-13 2016-11-17 Synlogic, Inc. Bactéries génétiquement modifiées pour réduire l'hyperphénylalaninémie
BR112017011923A2 (pt) * 2014-12-05 2018-02-27 Synlogic Inc bactéria modificada para tratar doenças associadas com hiperamonemia
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2016183532A1 (fr) 2015-05-13 2016-11-17 Synlogic, Inc. Bactéries modifiées pour traiter une maladie ou un trouble
AU2016276973B2 (en) * 2015-06-10 2022-09-01 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (fr) * 2015-06-24 2016-12-29 Synlogic, Inc. Bactéries recombinantes modifiées pour la biosécurité, compositions pharmaceutiques, et leurs procédés d'utilisation
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism

Also Published As

Publication number Publication date
IL255616A (en) 2018-01-31
IL255616B (en) 2022-10-01
US10195234B2 (en) 2019-02-05
PL3294760T3 (pl) 2021-11-08
IL296538A (en) 2022-11-01
US20170312320A1 (en) 2017-11-02
US10933102B2 (en) 2021-03-02
EP3294760B1 (fr) 2021-03-24
BR112017024384A2 (pt) 2018-07-24
US20170014457A1 (en) 2017-01-19
AU2016262569B2 (en) 2021-05-06
JP7245271B2 (ja) 2023-03-23
US20160340665A1 (en) 2016-11-24
JP6843768B2 (ja) 2021-03-17
EP3882259A1 (fr) 2021-09-22
JP2023085295A (ja) 2023-06-20
IL255616B2 (en) 2023-02-01
WO2016183531A1 (fr) 2016-11-17
AU2016262569A1 (en) 2018-01-04
US9943555B2 (en) 2018-04-17
AU2021212141A1 (en) 2021-08-26
US20180169154A1 (en) 2018-06-21
US9889164B2 (en) 2018-02-13
US20200246394A1 (en) 2020-08-06
ES2881384T3 (es) 2021-11-29
JP2021097685A (ja) 2021-07-01
JP2018515106A (ja) 2018-06-14
CA2985819A1 (fr) 2016-11-17
US20180280451A9 (en) 2018-10-04
US10610546B2 (en) 2020-04-07
AU2016262569B9 (en) 2021-09-16
ZA201707678B (en) 2021-03-31
EP3294760A1 (fr) 2018-03-21
US20170136073A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
ZA201707678B (en) Bacteria engineered to reduce hyperphenylalaninemia
IL278150A (en) A transgenic bacterium for the treatment of diseases related to hyperammonemia
HK1257676A1 (zh) 工程化 crispr-cas 9 核酸酶
HK1252666A1 (zh) 針對cd40的抗體
PL3377518T3 (pl) Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii
GB201514489D0 (en) Hyperphenylalaninemia
HK1252613A1 (zh) 作為cot調節劑的6-氨基-喹啉-3-腈
GB2541833B (en) Improvements to implant surfaces
GB201409541D0 (en) Probiotic Bacteria
GB201408039D0 (en) Culture dish
GB201515330D0 (en) Bioreactor condenser
GB201519450D0 (en) Novel treatment
GB2538045B (en) Improvements to letter-plates
HUE044168T2 (hu) Továbbfejlesztett fermentor
GB201514420D0 (en) Bioreactor
HK1253094A1 (zh) 多肽組合物
GB201520827D0 (en) Bioreactor
GB201514734D0 (en) Mechanical bioreactor
GB2522473B (en) Improvements to windposts
GB201517420D0 (en) Improvements to bedpans
GB201518810D0 (en) Bioreactor
GB201517290D0 (en) Bioreactor
GB201521028D0 (en) Improvements to Li-fi
GB2520781B (en) Improvements to hydro-turbines
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny